Locomotion and muscle mass measures in a murine model of collagen-induced arthritis

BMC Musculoskeletal Disorders

Volumn 10, Issue 1, 2009, Pages

  Hartog, Anita ^a,b   Hulsman, Judith ^c   Garssen, Johan ^a,b  

^a DANONE RESEARCH   (Netherlands)

^b UTRECHT UNIVERSITY   (Netherlands)

^c WAGENINGEN UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGEN; EMTHEXATE PF; METHOTREXATE; UNCLASSIFIED DRUG; ANTIRHEUMATIC AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; DRUG EFFICACY; EXPERIMENTAL MODEL; FUNCTIONAL ASSESSMENT; HINDLIMB; LOCOMOTION; MALE; MOUSE; MUSCLE MASS; NONHUMAN; RHEUMATOID ARTHRITIS; SCORING SYSTEM; ANIMAL; ARTHRITIS; BODY WEIGHT; CACHEXIA; DBA MOUSE; DISABILITY; DISEASE MODEL; DRUG EFFECT; HOSPITALIZATION; IMAGE PROCESSING; MUSCLE ATROPHY; NEUROLOGIC DISEASE; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; SKELETAL MUSCLE; TREATMENT OUTCOME; VIDEORECORDING;

ANIMALS; ANTIRHEUMATIC AGENTS; ARTHRITIS, EXPERIMENTAL; BODY WEIGHT; CACHEXIA; DISABILITY EVALUATION; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; GAIT DISORDERS, NEUROLOGIC; IMAGE PROCESSING, COMPUTER-ASSISTED; LOCOMOTION; MALE; METHOTREXATE; MICE; MICE, INBRED DBA; MUSCLE, SKELETAL; MUSCULAR ATROPHY; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; VIDEO RECORDING;

EID: 67651154611     PISSN: None     EISSN: 14712474     Source Type: Journal    
DOI: 10.1186/1471-2474-10-59     Document Type: Article

References (22)

1. Cachexia in rheumatoid arthritis. J Walsmith R Roubenoff, Int J Cardiol 2002 85 1 89 99 12163213
2. Rheumatoid cachexia: metabolic abnormalities, mechanisms and interventions. LC Rall R Roubenoff, Rheumatology (Oxford) 2004 43 10 1219 1223 15292530
3. Comparison of energy expenditure from lifestyle physical activities between patients with rheumatoid arthritis and healthy controls. CA Mancuso M Rincon W Sayles SA Paget, Arthritis Rheum 2007 57 4 672 678 17471544
4. Mechanisms of pain in arthritis. HG Schaible A Ebersberger GS Von Banchet, Ann N Y Acad Sci 2002 966 343 354 12114291
5. Proinflammatory cytokines and skeletal muscle. U Spate PC Schulze, Curr Opi Clin Nutr Metab Care 2004 7 3 265 269 15075917
6. Utility of animal models for identification of potential therapeutics for Rheumatoid Arthritis. M Hegen JC Keith Jr M Collins CL Nickerson-Nutter, Ann Rheum Dis 2007 18055474
7. Type II collagen autoimmunity in a mouse model of human rheumatoid arthritis. YG Cho ML Cho SY Min HY Kim, Autoimmun Rev 2007 7 1 65 70 17967728
8. Animal models of rheumatoid arthritis and their relevance to human disease. K Kannan RA Ortmann D Kimpel, Pathophysiology 2005 12 3 167 181 16171986
9. Anticytokine treatment of established type II collagen-induced arthritis in DBA/1 mice. A comparative study using anti-TNF alpha, anti-IL-1 alpha/beta, and IL-1Ra. LA Joosten MM Helsen FA van de Loo WB van den Berg, Arthritis Rheum 1996 39 5 797 809 8639177
10. Collagen-induced arthritis as a model of hyperalgesia: functional and cellular analysis of the analgesic actions of tumor necrosis factor blockade. JJ Inglis CA Notley D Essex AW Wilson M Feldmann P Anand R Williams, Arthritis Rheum 2007 56 12 4015 4023 18050216
11. Circadian pattern of spontaneous behavior in monarthritic rats: a novel global approach to evaluation of chronic pain and treatment effectiveness. M Millecamps D Jourdan S Leger M Etienne A Eschalier D Ardid, Arthritis Rheum 2005 52 11 3470 3478 16258901
12. FK506 ameliorates spontaneous locomotor activity in collagen-induced arthritis: implication of distinct effect from suppression of inflammation. T Sasakawa Y Sasakawa Y Ohkubo S Mutoh, Int Immunopharmacol 2005 5 3 503 510 15683847
13. Collagen-induced arthritis in mice. RO Williams, Methods Mol Med 2007 136 191 199 17983149
14. The genetic and immunopathological processes underlying collagen-induced arthritis. JA Luross NA Williams, Immunology 2001 103 4 407 416 11529930
15. The Open-Field Test: a critical review. RN Walsh RA Cummins, Psychol Bull 1976 83 3 482 504 17582919
16. Nutritional status in patients with rheumatoid arthritis. C Gomez-Vaquero JM Nolla J Fiter JM Ramon R Concustell J Valverde D Roig-Escofet, Joint Bone Spine 2001 68 5 403 409 11707006
17. Rheumatoid cachexia: cytokine-driven hypermetabolism accompanying reduced body cell mass in chronic inflammation. R Roubenoff RA Roubenoff JG Cannon JJ Kehayias H Zhuang B Dawson-Hughes CA Dinarello IH Rosenberg, J Clin Invest 1994 93 6 2379 2386 8200971
18. Cachexia: pathophysiology and clinical relevance. JE Morley DR Thomas MM Wilson, Am J Clin Nutr 2006 83 4 735 743 16600922
19. Waste management-cytokines, growth factors and cachexia. A Saini N Al-Shanti CE Stewart, Cytokine Growth Factor Rev 2006 17 6 475 486 17118696
20. Evidence from clinical trials and long-term observational studies that disease-modifying anti-rheumatic drugs slow radiographic progression in rheumatoid arthritis: updating a 1983 review. T Pincus G Ferraccioli T Sokka A Larsen R Rau I Kushner F Wolfe, Rheumatology (Oxford) 2002 41 12 1346 1356 12468813
21. Recent insights in the pharmacological actions of methotrexate in the treatment of rheumatoid arthritis. JA Wessels TW Huizinga HJ Guchelaar, Rheumatology (Oxford) 2008 47 3 249 255 18045808
22. Methotrexate specifically modulates cytokine production by T cells and macrophages in murine collagen-induced arthritis (CIA): a mechanism for methotrexate-mediated immunosuppression. MF Neurath K Hildner C Becker JF Schlaak K Barbulescu T Germann E Schmitt P Schirmacher S Haralambous M Pasparakis, Clin Exp Immunol 1999 115 1 42 55 9933419